In8Bio (INAB) Change in Accured Expenses (2020 - 2026)

In8Bio has reported Change in Accured Expenses for 7 years, with the latest figure at -$952000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 1071.43% year-over-year to -$952000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$464000.0 (down 285.6% YoY) and the FY2025 annual result came in at $586000.0, up 130.71% from the prior year.
• Change in Accured Expenses retreated to -$952000.0 in Q1 2026 per INAB's latest filing, from $1.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.2 million in Q4 2025 and troughed at -$2.1 million in Q1 2024.
• A 5-year average of -$32588.2 and a median of $98000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses surged 1246.67% in 2023, then plunged 1071.43% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$45000.0 in 2022, then surged by 1246.67% to $516000.0 in 2023, then sank by 46.51% to $276000.0 in 2024, then surged by 340.22% to $1.2 million in 2025, then tumbled by 178.35% to -$952000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$952000.0, $1.2 million, and -$217000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.